Lord’s Mark Biotech, a subsidiary of Lord’s Mark Industries, has launched Tinefcon, a patented medicine for treating Psoriasis in India. The company has signed an exclusivity agreement with INVEX Health Pvt Ltd for the patented product developed by Piramal Life Sciences in India. Tinefcon is being launched as a total solution for Psoriasis in four forms: tablet, cream, shower gel, and scalp wash. The company is mentoring mentors around the country through a scientific sales force exclusively recruited for Tinefcon.
Lord’s Mark Biotech has also established a strong social media campaign to aggressively market Tinefcon online which will be offered on internet marketplaces. The company has invested Rs. 20 Crores to market and distribute it extensively in India and expects a revenue of Rs.100 crores for Tinefcon by 2025.
The company’s MD, Sachidanand Upadhyay, expressed satisfaction with the launch and the company’s mission to enrich healthcare discourse in India. “We are pleased to introduce Tinefcon to the Indian market. The launch of Tinefcon is in line with our mission to enrich healthcare discourse in India.”
